Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Sector Perform Rating from Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reissued by research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $737.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would suggest a potential downside of 1.29% from the company’s current price.

REGN has been the subject of a number of other research reports. Citigroup raised their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Finally, Leerink Partners raised their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $802.18.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $5.58 during trading hours on Tuesday, reaching $746.67. 49,955 shares of the stock were exchanged, compared to its average volume of 826,360. The company has a market cap of $76.88 billion, a P/E ratio of 18.45, a price-to-earnings-growth ratio of 1.54 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a twelve month low of $541.00 and a twelve month high of $859.34. The stock has a 50 day moving average of $781.41 and a two-hundred day moving average of $720.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $12.81 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 4,146 shares of company stock worth $3,432,488. 6.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Nuveen LLC lifted its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $473,872,000. Bank of New York Mellon Corp bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $472,950,000. Finally, Deutsche Bank AG bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. 83.31% of the stock is currently owned by institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Libtayo cancer treatment is being evaluated in combination with Biohaven’s experimental BHV-1530 in patients with solid tumors, with enrollment in the combination cohort already underway. The agreement could support additional clinical applications and potential long-term growth for Libtayo. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results next month, making the upcoming earnings release a potential catalyst. Investors will likely focus on Eylea sales, operating performance and updates on the company’s broader pipeline. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Negative Sentiment: Kodiak Sciences reported Phase 3 data indicating that its investigational eye drugs, Zenkuda and tabirafusp alfa tedromer, matched Eylea on key efficacy endpoints for wet age-related macular degeneration. Their roughly six-month dosing interval, compared with Eylea’s typical eight-week schedule, raises concerns about future competitive pressure and potential pricing or market-share erosion. Kodiak skyrockets on positive study data for two eye drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $737 price target, below the reference price, signaling limited near-term upside in the analyst’s view. Royal Bank of Canada rating update

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.